A groundbreaking study reveals that high lipoproteina levels raise heart attack and stroke risks in both Asians and Europeans urging global attention to this hidden threat ...

Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 ...

Down syndrome patients have a 5.14 times higher risk of a stroke caused by a brain bleed, and more than 4 times higher risk ...

For patients with myocardial infarction (MI), early oral combination lipid-lowering therapy (LLT) is beneficial.

Advanced CKD was linked to a higher likelihood of both fatal and non-fatal adverse outcomes after acute myocardial infarction treatment. Patients with advanced chronic kidney disease (ACKD) with acute ...

Addition of revascularization to optimized medical therapy not beneficial in patients with carotid stenosis ≥50 percent and low or intermediate predicted stroke risk.

Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.

"Outcomes through 30 days and 1 year include the lowest 1-year stroke rates reported for any prospective, multicenter pivotal ...

The company's approved ANDA is therapeutically equivalent to AstraZeneca Pharmaceuticals's Brilinta Tablets, 60 mg and 90 mg, it added.

New findings from multiple studies demonstrate that glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of ...

The REVERSE-IT trial showed bentracimab effectively reversed the effects of ticagrelor, restoring platelet function with ...

Febuxostat does not appear to increase the risk for major adverse cardiovascular events when compared with no urate-lowering ...